Quest Diagnostics is set to acquire select assets from Fresenius Medical Care's Spectra Laboratories to enhance dialysis-related laboratory services in the U.S.

Target Information

Quest Diagnostics, a leading provider of diagnostic information services, has announced an agreement to acquire select assets from Fresenius Medical Care’s wholly owned Spectra Laboratories. This laboratory specializes in renal-specific testing services in the United States. The acquisition aims to enhance Quest's capabilities by adding dialysis-related water testing to its existing service portfolio, thereby reinforcing its commitment to improving patient care in the area of renal disease.

Fresenius Medical Care, headquartered in Bad Homburg, Germany, is the world’s largest provider of products and services for individuals suffering from renal diseases. With a network of 3,732 dialysis clinics globally, Fresenius serves approximately 308,000 patients through its extensive resources, including dialysis machines and related products.

Industry Overview

The chronic kidney disease (CKD) landscape in the United States is significant, affecting about 35.5 million adults, which equates to approximately 14% of the population. This condition represents one of the most prevalent and